90Singh and JainAlternative pathway of metronidazole activation in hamycin <strong>for</strong> Trichomonas vaginalis, HeLa and BHK-21. JTrichomonas vaginalis hydrogenosomes. Antimicrob Agents Antimicrob Chemother 36:795-802.Chemother 49:5033-5036.Lyons EJ and Carlton JM. 2004. Mind the gap: bridging theHrdy I, Hirt RP, Dolezal P, Bardonova L, Foster PG, Tachezy J divide between clinical and molecular studies of theand Embley TM. 2004. Trichomonas hydrogenosomes trichomonads. Trends Parasitol 20: 204-207.contain the NADH dehydrogenase module of mitochondrialcomplex I. Nature 432:618-621.McGrory T and Garber GE. 1992. Mouse intravaginal infectionwith Trichomonas vaginalis and role of LactobacillusHyun-Ouk S, Myeong-Heon S, Myoung-Hee A, Duk-Young M, acidophilus in sustaining Infection. Infect Immun 60:2375-Yong-Seok K and Jae-Sook R. <strong>2007</strong>. Trichomonas vaginalis: 2379.reactive oxygen species mediates caspase-3 dependentapoptosis of human neutrophils. Exp Parasitol Article inMeri T, Jokiranta TS, Suhonen L and Meri S. 2000. Resistance ofpress.Trichomonas vaginalis to metronidazole: report of the firstthree cases from Finland and optimization of in vitroInceboz T, Inceboz U and Ozturk S. 2004. Comparative in vitro susceptibility testing under various oxygen concentrations. Jcytotoxic effects of ornidazole, metronidazole and Clin Microbiol 38:763-767.ciprofloxacin against Trichomonas vaginalis trophozoites. JChemother 16:459-462.Mirhaghani A and Warton A. 1998. Involvement of Trichomonasvaginalis surface-associated glycoconjugates in theJean-Paul A, Lorna F and Huw S. 2005. Plant active components- parasite/target cell interaction. A quantitative electrona resource <strong>for</strong> antiparasitic agents? Trends in Parasitol microscopy study. Parasitol Res 84:374-381.21:462-468.Narcisi EM and Secor WE. 1996. In vitro effect of tinidazole andKoen WA, Rosnowsky S, Susanne WH, Putz S, Mark G, Martin furazolidone on metronidazole-resistant TrichomonasW, Jaap J, Aloysius GM and Henze K. 2008. vaginalis. Antimicrob Agents Chemother 40:1121-1125.Acetate:succinate CoA-transferase in the hydrogenosomesof Trichomonas vaginalis: identification and characteri-Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ and Vanacova S.zation. J Biol Chem 283 : 1411-1418.1998. Difficult-to-treat trichomoniasis: results withparomomycin cream. Clin Infect Dis 26: 986-988.Krieger JN, Ravdin JI and Rein MF. 1985. Contact-dependentcytopathogenic mechanisms of Trichomonas vaginalis.Petrin D, Delgaty K, Bhatt R and Garber G. 1998. Clinical andInfect Immun 50:778-786.microbiological aspects of Trichomonas vaginalis. ClinMicrobiol Rev 11:300-317.Kulda J. 1999. Trichomonads, hydrogenosomes and drugresistance. Int J Parasitol 29:199-212.Rasoloson D, Tomkova E, Cammack R, Kulda J and Tachezy J.2001. metronidazole -resistant strains of TrichomonasKulda J, Tachezy J and Cerkasovova A. 1993. In vitro induced vaginalis display increased susceptibility to oxygen.anaerobic resistance to MTZ in Trichomonas vaginalis. J Parasitol 123:45-56.Eukaryot Microbiol 40:262-269.Rasoloson D, Vanacova S, Tomkova E, Razga J, Hrdy I, TachezyLand KM, Delgadillo-Correa MG, Tachezy J, Vanacova S, Hsieh J and Kulda J. 2002. Mechanisms of in vitro development ofCL, Sutak R and Johnson PJ. 2004. Targeted gene resistance to metronidazole in Trichomonas vaginalis.replacement of a ferredoxin gene in Trichomonas vaginalis Microbiol 148:2467-2477.does not lead to metronidazole resistance. Mol Microbiol51:115-122.Ray DK, Tendulkar JS, Srivastava VB, Datta AK and NagarajanK. 1984. A metronidazole-resistant strain of TrichomonasLewis DA. 2005. Trichomoniasis. Medicine 33: 66-67.vaginalis and its sensitivity to Go 10213. J AntimicrobLockwood BC and Coombs GH. 1991. Purification andChemother 14:423-426.characterization of methionine y-lyase from Trichomonas Reguera RM, Tekwani BL and Balana-Fouce R. 2005.vaginalis. Biochem J 279:675-682.Polyamine transport in parasites: a potential target <strong>for</strong> newantiparasitic drug development. Comp Biochem PhysiolLoiseau PM, Bories C and Sanon A. 2002. <strong>The</strong> chitinase system140:151-164.from Trichomonas vaginalis as a potential target <strong>for</strong>antimicrobial therapy of urogenital trichomoniasis. Biomed Rowe AF and Lowe PN. 1986. Modulation of amino acid and 2-Pharmacother 56:503-510.oxo acid pools in Trichomonas vaginalis by aspartateaminotransferase inhibitors. Mol Biochem Parasitol 21:17-Lowe PN and Rowe AF. 1986. Aminotransferase activities in24.Trichomonas vaginalis. Mol Biochem Parasitol 21:65-74.Sanon A, Tournaire-Arellano C, Hage SYE, Bories C, Caujolle RLubick KJ and Burgess DE. 2004. Purification and analysis of aand Loiseau PM. 2005. N-acetyl-β-D-hexosaminidase fromphospholipase A2-like lytic factor of Trichomonas vaginalis.Trichomonas vaginalis: substrate specificity and activity ofInfect Immun 72:1284-1290.inhibitors. Biomed Pharmacother 59:245-248.Lushbaugh WB, Cleary JD and Finley RW. 1995. Cytotoxicity of
Chemotherapy of human trichomoniasis91Schmid G, Narcisi E, Mosure D, Secor WE, Higgins J and purpuromycin as potential topical agents <strong>for</strong> vaginalMoreno H. 2001. Prevalence of metronidazole-resistant infections. J Med Chem 40:967-971.Trichomonas vaginalis in a gynecology clinic. J Reprod MedTurner AC and Lushbaugh WB. 1988. Trichomonas vaginalis:Schumacher MA, Lau AO and Johnson PJ. 2003. Structural basis characterization of its glutamate dehydrogenase. Expof core promoter recognition in a primitive eukaryote. Cell. Parasitol 67:47-53.115:370-372.Upcroft P and Upcroft JA. 2001. Drug targets and mechanisms ofSchwebke JR. 2002. Update of trichomoniasis. Sex Transm resistance in the anaerobic protozoa. Clin Microbiol RevInfect 78:378-379. 14:150-164.Schwebke JR and Burgess D. 2004. Trichomoniasis. Clin U.S. Food and Drug Administration. 2004. Index to drug-Microbiol Rev 17:794-803.specific in<strong>for</strong>mation. http://www.fda.gov/cder/Sobel JD, Nyirjesy P and Brown W. 2001. Tinidazole therapy <strong>for</strong>consumerinfo/tindamax.htm.metronidazole-resistant vaginal trichomoniasis. Clin Infect Vidakovic M, Crossnoe CR, Neidre C, Kim K, Krause KL andDis 33:1341-1346.Germanas JP. 2003. Reactivity of reduced [2Fe-2S]ferredoxins parallels host susceptibility to nitroimidazoles.Solano-Gonzaleza E, Alvarez-Sanchezb ME, Avila-GonzalezcAntimicrob Agents Chemother 47:302-308.L, Rodriguez-Vargasa VH, Arroyoc R and Ortega-Lopez J.2006. Location of the cell-binding domain of CP65, a 65 kDa Westrop GD, Goodall G, Mottram JC and Coombs GH. 2006.cysteine proteinase involved in Trichomonas vaginalis Cysteine biosynthesis in Trichomonas vaginalis involvescytotoxicity. Int J Biochem Cell Biol 38:2114-2127.cysteine synthase utilizing o-phosphoserine. J Biol ChemStrosselli S, Spadari S, Walker RT, Basnak I and Focher F. 1998.281:25062-25075.Trichomonas vaginalis thymidine kinase: purification, World Health Organization. 2001. Global prevalence andcharacterization and search <strong>for</strong> inhibitors. Biochem J 334:15- incidence of selected curable sexually transmitted infections.22. G e n e v a , S w i t z e r l a n d . h t t p : / / w w w. w h o . i n t /Sutak R, Dolezal P, Fiumera HL, Hrdy I, Dancis A, Delgadillodocstore/hiv/GRSTI/006.htm.Correa M, Johnson PJ, Müller M and Tachezy J. 2004. Yadav M, Dubey ML, Gupta I, Bhatti G and Malla N. <strong>2007</strong>.Mitochondrial-type assembly of FeS centers in the Cysteine proteinase 30 in clinical isolates of T. vaginalis fromhydrogenosomes of the amitochondriate eukaryote symptomatic and asymptomatic infected women. ExpTrichomonas vaginalis. 101:10368-10373. Parasitol 116:399-406.Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Yarlett N and Bacchi CJ. 1988. Effect of DL-alpha-Zenilman JM, Marzo AM, Willett WC and Platz EA. 2006. difluoromethylornithine on polyamine synthesis andPlasma antibodies against Trichomonas vaginalis and interconversion in Trichomonas vaginalis grown in a semisubsequentrisk of prostate cancer. Cancer Epidemiol defined medium. Mol Biochem Parasitol 31:1-9.Biomarker Preven 15:939-945.Zang Y, Wen-Hu W, Shaw-Wen W, Ealick SE and Wang CC.Tachezy J, Kulda J and Tomokova E. 1993. Aerobic resistance of 2005. Identification of a subversive substrate of TrichomonasTrichomonas vaginalis to metronidazole induced in vitro. vaginalis purine nucleoside phosphorylase and the crystalParasitol 106:31-37.structure of the enzyme-substrate complex. J Biol ChemThappa DM. 2006. Evolution of venereology in India. Ind J280:22318-22325.Dermatol Venerol Leprol 72:187-196.Zariffard MR, Harwani S, Novak RM, Graham PJ, Ji X and SpearGT. 2004. Trichomonas vaginalis infection activates cellsTrani A, Dallanoce C, Panzone G, Ripamonti F, Goldstein BPthrough toll-like receptor 4. Clin Immunol 111:103-107.and Ciabatti R. 1997. Semisynthetic derivatives of